Seer Inc(SEER) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Morgan Stanley Maintains Seer Inc(SEER.US) With Hold Rating, Maintains Target Price $3
Moomoo NewsMar 14 13:31 ET · Ratings
Galorath Appoints David Rampton as Director of AI-Driven Cost Engineering and Analysis to Support AI Platform Deployment
PR NewswireMar 11 06:15 ET
Down -10.53% in 4 Weeks, Here's Why Seer (SEER) Looks Ripe for a Turnaround
Zacks Mar 6 08:40 ET
Seer Inc | 10-K: FY2024 Annual Report
SECMar 3 16:19 ET · Announcements
Earnings Call Summary | Seer Inc(SEER.US) Q4 2024 Earnings Conference
moomoo AIFeb 27 22:24 ET · Conference Call
TD Cowen Maintains Seer Inc(SEER.US) With Buy Rating
Moomoo NewsFeb 27 21:31 ET · Ratings

Comments

Jaguar8

Oct 31, 2024 19:08

NEWS

$Seer Inc (SEER.US)$
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
Seer will showcase its Proteograph Product Suite at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, demonstrating how deep proteomics enhances genomic research. The company will present breakthrough research in lung cancer and Alzheimer's Disease through a CoLab session featuring PrognomiQ and Salk Institute.
Key highlights incl...

1

Jaguar8

Jun 12, 2024 01:48

NEWS

$Seer Inc (SEER.US)$
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer has published three papers demonstrating its Proteograph Product Suite's ability to uncover novel plasma proteomic insights during spaceflight. Data from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with many alterations persisting six months post-flight. Seer’s tech...

2

Jaguar8

Jun 2, 2024 23:39

NEWS

$Seer Inc (SEER.US)$
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
Seer has announced the completion of a groundbreaking mass spectrometry study by PrognomiQ, utilizing Seer's Proteograph Product Suite and the Thermo Scientific Orbitrap Astral mass spectrometer. This multi-cancer case-control study involved 2,840 subjects and identified over 13,000 protein groups, with an average of 8,200 protein groups per sample...

Moomoo AI

Nov 17, 2023 18:35

While Seer is forecasted to have more rapid revenue growth than the wider market, the stark decrease in revenue estimates might cause investors to be more cautious about the company.